BAX SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Announces that Baxter Investors Have Opportunity to Lead Class Action Lawsuit

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Baxter International Inc. due to allegations of federal securities law violations related to the Novum LVP device, which reportedly suffered systemic defects leading to serious patient risks [3][4]. Group 1: Allegations Against Baxter - The complaint alleges that Baxter and its executives made false or misleading statements regarding the Novum LVP, failing to disclose systemic defects that caused malfunctions, including underinfusion and overinfusion, which posed risks of serious injury or death to patients [3]. - Baxter was reportedly aware of multiple device malfunctions, injuries, and deaths but did not take adequate remedial measures, leading to continued harm to patients [3]. - As a result of these issues, there was a heightened risk that existing Novum LVPs would be taken out of service, and Baxter would halt all new sales of these pumps [3]. Group 2: Impact on Stock and Legal Proceedings - The true extent of the alleged fraud was revealed on July 31, 2025, when Baxter announced a voluntary and temporary pause in shipments and installations of the Novum LVP, resulting in a 22.4% drop in stock price, closing at $21.76 [4]. - Investors who purchased Baxter securities between February 23, 2022, and July 30, 2025, are encouraged to discuss their legal rights and options, with a deadline of December 15, 2025, to seek the role of lead plaintiff in the class action [1][5].